How to Monitor Psilocybin Treatment for Chronic Suicidal Ideation
How should clinicians monitor response and safety after a single psilocybin dose in patients with chronic suicidal ideation?
Even in a supportive setting, psilocybin treatment for chronic suicidal ideation produced both substantial improvement and occasional worsening. This guide focuses on the study's actual monitoring workflow, which tracked suicidal ideation, depression, and adverse events at defined time points after dosing.
-
Measure baseline suicidal ideation and depression before dosing
Establish pretreatment severity using the Modified Scale for Suicidal Ideation and the Montgomery-Asberg Depression Rating Scale. The study used baseline values for both efficacy analyses and later determination of antisuicidal response, defined as at least 50% reduction in MSSI.
-
Reassess at weeks 1, 3, and 12
Repeat MSSI and MADRS assessments at week 1, week 3, and week 12 after dosing. Week 3 was the primary efficacy end point in the study, while weeks 1 and 12 were used to evaluate early change and durability.
-
Track suicidal ideation directly with C-SSRS at each visit
Use the Columbia-Suicide Severity Rating Scale at each follow-up visit as a supplementary safety measure. In the study, a clinician administered the C-SSRS to systematically evaluate suicidal ideation severity and suicidal behavior and to guide risk monitoring and clinical escalation when indicated.
-
Classify response and remission using study thresholds
Interpret improvement with the same thresholds used in the trial: antisuicidal response was at least 50% reduction from baseline MSSI, and suicidal ideation remission was MSSI equal to 0. At week 12, the article also highlighted minimal residual ideation as MSSI scores of 1 or 2.
-
Document all treatment-emergent adverse events
At each study visit, systematically monitor and record treatment-emergent adverse events. The article states that adverse events were coded with MedDRA and judged by the study physician for severity as mild, moderate, or severe and for relationship to the intervention based on consistency with known pharmacologic effects of psilocybin.
-
Watch closely for anxiety reactions and worsening suicidality
Maintain vigilance for acute anxiety during dosing and for later worsening in suicidal ideation during follow-up. In the study, 1 participant with comorbid PTSD required rescue lorazepam on the dosing day and as-needed clonazepam for 3 weeks afterward, and 2 of 20 participants had MSSI increases above baseline, including 1 participant whose score increased from 17 at baseline to 23 at week 12.
-
Interpret long-term follow-up in light of medication changes
When reviewing durability beyond week 3, account for restarted or newly initiated psychotropic treatment. In this cohort, 12 of 20 participants restarted or initiated at least 1 psychotropic medication for major depressive disorder at or after week 3, which complicates attribution of longer-term outcomes to psilocybin alone.
Clinical Considerations
- Improvement in depressive symptoms should not replace direct suicidal ideation monitoring, even though MSSI and MADRS changes were strongly correlated.
- A favorable overall safety profile did not eliminate risk, because 10% of participants had increased MSSI scores relative to baseline during follow-up.
- The slight upward drift in mean MSSI from week 1 to weeks 3 and 12 suggests some symptom return over time despite continued improvement versus baseline.
- Long-term outcomes after week 3 are harder to attribute to psilocybin alone because 60% of participants restarted or initiated psychotropic medication during follow-up.
Bottom Line
After psilocybin dosing, monitor suicidal ideation directly and repeatedly at weeks 1, 3, and 12 with formal scales and adverse-event review, because early benefit can coexist with later symptom return or worsening in a subset of patients.
